BioCentury | Oct 24, 2013
Strategy

Synaptic synopsis

...a large number of mutated proteins involved in pathways that converge on glutamate synapses. 6 Seaside Therapeutics Inc....
...Inc. (NYSE:PFE), New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Sage Bionetworks , Seattle, Wash. Seaside Therapeutics Inc....
...I Depression AMPA glutamate receptor (GRIA; GLUR) Pfizer Inc. (NYSE:PFE) PF-04958242 Phase I Schizophrenia mGluR5 Seaside Therapeutics Inc....
BioCentury | May 27, 2013
Company News

Seaside Therapeutics, Roche deal

...indication, the Phase III Study 209FX302, are expected "late summer." Seaside declined to disclose details. Seaside Therapeutics Inc....
BioCentury | May 22, 2013
Company News

Roche declines to exercise STX209 option

...Roche (SIX:ROG; OTCQX:RHHBY) said it declined to exercise its option to license STX209 from Seaside Therapeutics Inc. (Cambridge...
BioCentury | May 6, 2013
Clinical News

STX209: Phase IIb data

...of Phase III trials of STX209 to treat fragile X syndrome are expected this year. Seaside Therapeutics Inc....
BioCentury | May 2, 2013
Clinical News

Seaside's STX209 misses in Phase IIb trial for autism

Seaside Therapeutics Inc. (Cambridge, Mass.) said oral STX209 for 12 weeks missed the primary endpoint vs. placebo in the Phase IIb Study 209AS208 to treat autism spectrum disorders (ASD). Specifically, STX209 missed the primary endpoint...
BioCentury | Feb 14, 2013
Distillery Therapeutics

Indication: Neurology

...lovastatin is an HMG-CoA reductase inhibitor marketed to treat dyslipidemia and coronary artery disease (CAD). Seaside Therapeutics Inc.'s...
BioCentury | Feb 14, 2013
Targets & Mechanisms

Statins for fragile X

...and brain receptors that regulate translation. 2 Three companies- Novartis AG and Roche and partner Seaside Therapeutics Inc....
...Technology , Cambridge, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Seaside Therapeutics Inc....
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
BioCentury | Dec 10, 2012
Company News

Seaside Therapeutics, Autism Speaks neurology news

...to partner with industry to progress autism research (see BioCentury, June 25 & Oct. 29). Seaside Therapeutics Inc....
BioCentury | Oct 8, 2012
Product Development

Contrarian thinking

...receptor agonist Fragile X syndrome; autism spectrum disorders Ph III [Fragile X]; Ph II [autism] Seaside Therapeutics Inc./Roche...
Items per page:
1 - 10 of 42
BioCentury | Oct 24, 2013
Strategy

Synaptic synopsis

...a large number of mutated proteins involved in pathways that converge on glutamate synapses. 6 Seaside Therapeutics Inc....
...Inc. (NYSE:PFE), New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Sage Bionetworks , Seattle, Wash. Seaside Therapeutics Inc....
...I Depression AMPA glutamate receptor (GRIA; GLUR) Pfizer Inc. (NYSE:PFE) PF-04958242 Phase I Schizophrenia mGluR5 Seaside Therapeutics Inc....
BioCentury | May 27, 2013
Company News

Seaside Therapeutics, Roche deal

...indication, the Phase III Study 209FX302, are expected "late summer." Seaside declined to disclose details. Seaside Therapeutics Inc....
BioCentury | May 22, 2013
Company News

Roche declines to exercise STX209 option

...Roche (SIX:ROG; OTCQX:RHHBY) said it declined to exercise its option to license STX209 from Seaside Therapeutics Inc. (Cambridge...
BioCentury | May 6, 2013
Clinical News

STX209: Phase IIb data

...of Phase III trials of STX209 to treat fragile X syndrome are expected this year. Seaside Therapeutics Inc....
BioCentury | May 2, 2013
Clinical News

Seaside's STX209 misses in Phase IIb trial for autism

Seaside Therapeutics Inc. (Cambridge, Mass.) said oral STX209 for 12 weeks missed the primary endpoint vs. placebo in the Phase IIb Study 209AS208 to treat autism spectrum disorders (ASD). Specifically, STX209 missed the primary endpoint...
BioCentury | Feb 14, 2013
Distillery Therapeutics

Indication: Neurology

...lovastatin is an HMG-CoA reductase inhibitor marketed to treat dyslipidemia and coronary artery disease (CAD). Seaside Therapeutics Inc.'s...
BioCentury | Feb 14, 2013
Targets & Mechanisms

Statins for fragile X

...and brain receptors that regulate translation. 2 Three companies- Novartis AG and Roche and partner Seaside Therapeutics Inc....
...Technology , Cambridge, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Seaside Therapeutics Inc....
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
BioCentury | Dec 10, 2012
Company News

Seaside Therapeutics, Autism Speaks neurology news

...to partner with industry to progress autism research (see BioCentury, June 25 & Oct. 29). Seaside Therapeutics Inc....
BioCentury | Oct 8, 2012
Product Development

Contrarian thinking

...receptor agonist Fragile X syndrome; autism spectrum disorders Ph III [Fragile X]; Ph II [autism] Seaside Therapeutics Inc./Roche...
Items per page:
1 - 10 of 42